SCHEMBL4871862

SCHEMBL4871862

CC(C)(C)N(CCCN)Cc1ccc(Cl)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 2/20 0.48
PNMT P11086 2/20 0.46
TAAR1 Q96RJ0 1/20 0.46
SIGMAR1 Q99720 8/20 0.43
CYP1A2 P05177 2/20 0.41
CYP2C19 P33261 2/20 0.41
SLC6A2 P23975 2/20 0.41
SLC6A4 P31645 2/20 0.41
SLC6A3 Q01959 2/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
KCNH2 Q12809 1/20 0.41
PYCR1 P32322 1/20 0.41
CARM1 Q86X55 1/20 0.39
PRMT1 Q99873 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2538061 0.80 SIGMAR1 (0.58) GBA1PNMTTAAR1SIGMAR1CYP1A2
SCHEMBL4636336 0.76 CYP1A2 (0.52) GBA1PNMTTAAR1SIGMAR1CYP1A2
SCHEMBL4760458 0.72 SIGMAR1 (0.59) PNMTTAAR1SIGMAR1CYP1A2CYP2C19
SCHEMBL17788590 0.72 PYCR1 (0.53) PNMTTAAR1SIGMAR1CYP1A2CYP2C19
SCHEMBL18135502 0.70 S1PR1 (0.35) SIGMAR1CYP1A2CYP2C19SLC6A2SLC6A4
SCHEMBL25587803 0.70 CYP1A2 (0.40) GBA1SIGMAR1CYP1A2CYP2C19CYP2D6
SCHEMBL4037320 0.69 PNMT (0.76) PNMTTAAR1SIGMAR1CYP1A2CYP2C19
SCHEMBL9160104 0.68 SIGMAR1 (0.67) PNMTTAAR1SIGMAR1CYP1A2CYP2C19
SCHEMBL9640729 0.68 CHRM2 (0.38) MEN1ALDH1A1KMT2A
SCHEMBL31497388 0.68 PNMT (0.73) PNMTTAAR1SIGMAR1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287434-A1 New amino-alkyl-amide derivatives as CCR3 receptor ligands SANOFI-AVENTIS (FR) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287434-A1 New amino-alkyl-amide derivatives as CCR3 receptor ligands CCR3, CCR1, CCR4 GBA1 992/4885PNMT 3149/4885TAAR1 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.